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Background: We aimed to find different proteins between dendritic cells (DCs) and tumor antigen-pulsed DCs to
help find a new biomarker for endometrial cancer (EC).
Methods: Mononuclear cells were isolated from cord blood and induced to DCs by cytokines. A comparative
proteomic analysis was performed on DCs and tumor lysate-pulsed DCs by liquid chromatography with tandem
mass spectrometry (LC-MS/MS). Differential proteins were identified by Western blot analysis.
Results: The expression of Ras-related protein Rab-8A (RAB8A) was found to be different in the in two kinds of cells.
This phenomenon was also proven in endometrial cancer tissues.
Conclusions: RAB8A might be a new biomarker for endometrial cancer. Using LC-MS/MS to perform a comparative
proteomic analysis about DCs and tumor lysate-pulsed DCs may help us to find new biomarker of cancer.
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Endometrial cancer (EC) is a common gynecological ma-
lignancy and the incidence is gradually increasing due to
life patterns [1]. Current methods of diagnosis of EC rely
on invasive techniques, such as biopsy and curettage.
There are no specific tumor markers for EC. Identifica-
tion of tumor antigens is important not only for studying
antitumor immune responses and immunotherapy, but
also for the development of diagnostic methods [2].
It is known that dendritic cells (DCs) are the most po-
tent antigen-presenting cells and can be derived ex vivo
from monocytes of blood by using GM-CSF (granulo-
cyte-macrophage colony-stimulating factor) and IL-4
(Human interleukin 4) [3]. Immunotherapy with DCs has
been studied in a wide variety of cancers and has demon-
strated the induction of tumor-specific immune responses.
Therefore, we assumed that protein expressions of DCs
are different before and after pulsing with tumor lysate.
The results could be useful in helping to find tumor-
specific antigens of EC between these differences. We per-
formed a comparative proteomic analysis of DCs and
tumor lysate-pulsed DCs by liquid chromatography with
tandem mass spectrometry (LC-MS/MS). We used the
HEC-1-B cell line of EC to prepare the tumor lysate.* Correspondence: bjzhangzhy@sina.cn
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Informed consent was obtained from all the patients be-
fore enrollment in the study. This study was approved
by the institutional Ethics Committees of Beijing Chao-yang
Hospital affiliated to Capital Medical University and con-
ducted in accordance with the ethical guidelines of the
Declaration of Helsinki.
Cell line culture medium and tumor lysate preparation
HEC-1-B cells were cultured in DMEM/F12 (dulbecco's
modified eagle medium) (HyClone, Waltham, Massachusetts,
United States) medium supplemented with penicillin (10
IU/ml), streptomycin (100 ug/ml), and 10% fetal bovine
serum (FBS, Gibco, Carlsbad, California, United States),
and in a humidified atmosphere of 5% CO2 at 37°C. They
were harvested when there was 80 to 90% confluent and
rinsed twice with PBS. 1 × 107/ml cells were lysed by five
freeze cycles in liquid nitrogen and thaw cycles at room
temperature. They were then centrifuged at 400 g for
10 minutes, then supernatants were passed through a
0.2 um filter (PAll Acrodisc® United States) and stored
at −80°C [4].
Isolation of umbilical cord blood mononuclear cells and
generation of dendritic cells
Umbilical cord blood samples were collected from normal
full-term deliveries after obtaining written informed con-
sent. Umbilical cord blood mononuclear cells (UBMCs)al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(200 IU/ml) by Ficoll-Hypaque 1.077 g/ml (Gibco-
Invitrogen, Paisley, United Kingdom), subjected to density
gradient centrifugation and placed into six-well culture
plates in RPMI (Roswell Park Memorial Institute) 1640
medium plus 10% FBS (Gibco-BRL Gaithersburg, Maryland,
United States) at 1 × 106/2 ml per well. After two hours at
37°C in a humidified 5% CO2 incubator, nonadherent cells
were removed, and the adherent cells were cultured in
same medium supplemented with recombinant human
GM-CSF (1,000 U/ml) and IL-4 (1,000 U/ml) (PeproTech,
United States). Every three days, 1 ml of spent medium
was replaced by 2 ml of fresh medium containing GM-CSF
and IL-4, to yield final concentrations of 1,000 U/ml.
Dendritic cell pulsing
After five days of culture, immature DCs were harvested
and suspended in medium with GM-CSF and IL-4 at
1 × 106/ml and mixed with tumor lysate at ratios of 1:10.
DCs with or without antigen loading were harvested on
the seventh day.
Flow-based analysis of labeled cells
Cells were washed with PBS twice and incubated in a
10% FcR-blocking solution (Miltenyi Biotec Bergisch
Gladbach, Germany) for 30 minutes at 4°C to block the
nonspecific binding to FcR. Then, cells were stained with
PE- or APC-conjugated antibodies. Control staining was
performed simultaneously using isotype-matched, irrele-
vant antibodies also directly conjugated to PE or APC. The
fluorescence intensity of the cells was analyzed by flow cy-
tometry (FACS Calibur; Becton Dickinson, United States).
The antibodies used are PE-conjugated anti-CD80 and
HLA-DR (BD Biosciences, United States) and APC-
conjugated anti-CD11c (BD Biosciences, United States).
Sample preparation for LC-MS/MS
Cells, including DCs and DCs with HEC-1-B cells lysate-
pulsed, were washed twice with ice-cold PBS containing
protease inhibitors and sonicate in ice-cold RIPA buffer
(Sangon Biotech, Shanghai, China) and centrifuged at
1,000g at 4°C for 10 minutes. The supernatant proteins
were boiled for five minutes before analysis on 12% poly-
acrylamide gels (Sangon Biotech, Shanghai, China). Protein
concentrations were determined with the bicinchoninic
acid (BCA) method (Thermo Scientific, United States).
Gels were placed in a staining solution (1.3 M ammonium
sulfate, 34% methanol, 1.4% orthophosphoric acid and
0.07% Coomassie Brilliant Blue G250 (Sangon Biotech,
Shanghai, China) for 24 hours, and then were de-stained
until the background was clear. Coomassie Blue-stained
protein bands were excised from the SDS-PAGE gel. Gel
pieces were de-stained twice for 10 minutes in a solution
containing 100 mM NH4HCO3 and 50% acetonitrile,dehydrated in acetonitrile, and dried in a vacuum centri-
fuge. Then, gel pieces were rehydrated at 4°C for 45 mi-
nutes in a digestion buffer (50 mM NH4HCO3 and 12.5
ng/ul trypsin). The supernatant was replaced by 40 ul of 50
mM NH4HCO3 and the samples were incubated overnight
at 37°C. The tryptic peptides were recovered by 10-minute
incubations, once in 25 mM NH4HCO3 and 50% aceto-
nitrile, and twice in 25 mM NH4HCO3, 50% acetonitrile
and 5% formic acid (Sangon Biotech, Shanghai, China). All
supernatants were pooled and dried in a vacuum centri-
fuge [5].
The resulting peptides were analyzed by LC-MS/
MS using a capillary LC system (Magic2002; Michrom
BioResources, Auburn, California, United States) coupled
to an inline nano-electrospray mass spectrometer (LCQ
Advantage; Thermo Finnegan, Waltham, Massachusetts,
United States) with a silica-coated glass capillary tube
(PiclTip; New Objective, Woburn, Massachusetts, United
States). Raw LC-MS/MS data were analyzed by searching
the Mascot database [6] to identify the proteins. To gener-
ate a statistically valid list of proteins, Scaffold, United
States was used to accommodate differences of algorithm
and score calculation by the two search engines [7].
Western blotting
Western blotting analysis was used to validate the findings.
Total proteins were extracted using a RIPA kit (Beyotime,
Shanghai, China) containing a 1% dilution of the pro-
tease inhibitor PMSF (Phenylmethanesulfonyl fluoride)
(Beyotime, Shanghai, China). Protein concentrations were
determined with the BCA method. Proteins (50 ug/lane)
were separated by 12% SDS-PAGE and transferred to a
0.2 um PVDF (Polyvinylidene Fluoride, Beyotime, Shang-
hai, China) membrane (Millipore, Billerica, Massachusetts,
United States). After blocking the membrane in blocking
buffer (5% milk powder in 20 mM Tris-HCl pH 7.5, 500
mM NaCl, 0.1% (v/v) Tween 20 (Beyotime, Shanghai,
China), the membrane was incubated with primary anti-
bodies against RAB8A (1:1,000; Proteintech, United States)
and tubulin (1:2,000, Cell Signaling Technology, United
States) at 4°C overnight. Peroxidase-linked secondary anti-
rabbit or anti-mouse antibodies were used to detect
the bound primary antibodies. Enhanced chemilumines-
cence (ECL) reagents (Santa Cruz) were used to visualize
(Bio-rad, United States).
Results
Figure 1 is flow cytometric analysis result. Figure 1A to C
show that the DCs were cultured using UBMC by the
adherent method and Figure 1D to F show that the DCs
were pulsed with HEC-1-B cell lysate. The cells were
harvested at the seventh day of culture. The cells in
the gated population were further analyzed and found to be
CD11C+/HLA-DR+ (Figure 1B and E) and CD11C+/CD80+
Figure 1 Flow cytometric analysis of the seventh day DCs. A-C show the cells were cultured by the adherent method, and D-F show
that the DCs were pulsed with HEC-1-B cell lysate. The cells were harvested at the seventh day of culture. The cells in the gated
population were further analyzed and found to be CD11C+/HLA-DR+ (B, E) and CD11C+/CD80+ (C, F). DCs dendritic cells.
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we can conclude that the tumor cell lysate of EC can
mature DCs.
Protein expression of cells, including DCs and DCs with
HEC-1-B cell lysate pulsed (HEC-DCs), were analyzed by
LC-MS/MS. We found 136 upregulated proteins and 110
downregulated proteins in HEC-DCs compared with DCs.
Figure 2 shows the comparison of protein function be-
tween upregulated and downregulated proteins. Some pro-
teins that were upregulated were chosen to be analyzed by
Western blotting. We found that the expression of Ras-
related protein Rab-8A (RAB8A) is significantly higher
in HEC-DC than in DCs (Figure 3). We also compared its
expression in tissues of healthy and malignant endomet-
rium. A significant increase of RAB8A in EC versus healthy
controls was observed (P <0.05) (Figure 4).
Discussion
In the early 1970s, DCs were first identified [8]. Now it is
widely recognized that DCs are the major antigen-presenting
cells (APCs) to T-lymphocytes, which not only initiate,but also control cellular immune responses [9]. Most pub-
lished research show results from experiments using mag-
netic activated cell sorting (MACS) separation CD34+
cells from cord blood to induce DCs. In this study, we also
induce DCs from cord blood using the adherent method;
proven by flow cytometric analysis. We also show that the
HEC-1-B tumor cell lysate can mature DCs.
From the comparative proteomic analysis by LC-MS/MS,
functions of transporter activity, catalytic activity and anti-
oxidant activity are higher in upregulated proteins. Some
proteins, such as Vimentin (VIM), Rho GDP-dissociation
inhibitor 1 (Rho GDI), Lysosome-associated membrane
glycoprotein 1 (LAMP1) and Membrane-associated pro-
gesterone receptor component 2 (PGRMC 2), have been
previously identified as potential biomarkers for various
cancers [10-14]. By reviewing articles, only one of them
has been studied in EC [15].
In our study, we found a significant increase of RAB8A
in EC, which is a small GTPase belonging to the rab family
of ras-GTPases, and is also a marker of recycling endo-
somes [16]. RabGTPases are major regulators of intracellular
Figure 2 The comparison of protein function between upregulated and downregulated proteins. Functions of transporter activity, catalytic
activity and antioxidant activity are significantly higher in upregulated proteins (P <0.05).
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regulatory function considered to be restricted to the
membrane compartments where they are located [17]. Al-
terations in Rab-GTPase expression or activity can cause
defects in cell adhesion, motility and invasion, leading
to neurologic diseases, lipid storage disorders or cancer
[18]. Recently, RAB8A was found to control cell surface
exposure of MT1-MMP (membrane type-1 matrix metal-
loproteinase), extracellular matrix degradation and three-
dimensional invasion of macrophages [17]. MT1-MMP is
thought to play a key role in tumor invasion. The highest
expression of RAB8 was at an early stage of cisplatin re-
sistance. RAB8 and TMEM205 indicated an additive effect
of mediating cisplatin resistance [19].
Sun et al. [20] concluded that RAB13 and RAB8A are
Rab-GTPases activated by insulin, and that downstream
of AS160 they regulate traffic of GLUT4(Glucose trans-
porter 4) vesicles, possibly acting at distinct steps and
sites. These findings close in on the series of events
regulating muscle GLUT4 traffic in response to insulin,
crucial for whole-body glucose homeostasis [20]. Our re-
search may help to explain the cause of EC in patients
with obesity and diabetes.Figure 3 The expression of RAB8A in cells. The expression of
RAB8A is significantly higher in HEC-DC than in DC and HEC-1-B cells
as analyzed by Western-blot (P <0.05). DCs dendritic cellsConclusions
The adherent method can be used in cord blood to induce
DCs. As DCs are the most potent antigen-presenting cells,
we used this character to perform a comparative prote-
omic analysis of DCs and tumor lysate-pulsed DCs by
LC-MS/MS, and found the expression of RAB8A to be
significantly higher in HEC-DC and malignant endomet-
rium tissues. We hypothesize that RAB8A may participateFigure 4 The expression of RAB8A in healthy and malignant
endometrium tissues (A, B). A significant increase of RAB8A in EC
versus the healthy controls was observed by Western blot analysis
(P <0.05). (A) the image of Western-blot in EC and healthy tissues;
(B) Analysis of the Western-blot image results in EC and healthy
tissues. EC endometrial cancer.
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http://www.wjso.com/content/12/1/371in the progression of malignant growth of EC. How-
ever, it is still too early to conclude RAB8A as a novel
biomarker for EC diagnosis. The role of RAB8A in EC
needs to be further studied. We hope our results will pro-
vide useful information for studies on the detection and
therapy of EC.
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